Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of LY03005 Under Fed vs Fasted Conditions
NCT03822065Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of toludesvenlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Pharmacokinetic Parameters at 72 hours. Started Jan 2019; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03822065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822065.